首页|期刊导航|中华医学杂志（英文版）|Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024:From resmetirom to tirzepatide

Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024:From resmetirom to tirzepatide

Rui Huang Chunli Zhang Xiaodong Mo Huiying Rao

中华医学杂志（英文版）2025，Vol.138Issue(2)：127-129,3.

中华医学杂志（英文版）2025，Vol.138Issue(2)：127-129,3.DOI:10.1097/CM9.0000000000003417

Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024:From resmetirom to tirzepatide

Rui Huang ¹Chunli Zhang ²Xiaodong Mo ³Huiying Rao¹

作者信息

1. Peking University People's Hospital,Peking University Hepatology Institute,Infectious Disease and Hepatology Center of Peking University People's Hospital,Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases,Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis,Beijing 100044,China
2. Department of Hematology,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China
3. Peking University People's Hospital,Department of Hematology,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing 100044,China
折叠

摘要

引用本文复制引用

Rui Huang,Chunli Zhang,Xiaodong Mo,Huiying Rao..Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024:From resmetirom to tirzepatide[J].中华医学杂志（英文版）,2025,138(2):127-129,3.

基金项目

This work was supported by the National Key Research &Development Program of China(No.2022YFA1303804),Peking University People's Hospital Scientific Research Development Funds(No.RDJ2022-21),and Peking Univer-sity Hepatology Institute Qi-Min Project. （No.2022YFA1303804）

中华医学杂志（英文版）

ISSN：0366-6999

访问量0

下载量0

段落导航